Suppr超能文献

综合依从性监测系统:小儿肾移植中的实时非依从性风险评估

System for integrated adherence monitoring: real-time non-adherence risk assessment in pediatric kidney transplantation.

作者信息

Pai Ahna L H, Rausch Joseph, Tackett Alayna, Marsolo Keith, Drotar Dennis, Goebel Jens

机构信息

Center for the Promotion of Treatment Adherence and Self-Management, Cincinnati Children's Hospital Medical, Cincinnati,OH 45229-3039, USA.

出版信息

Pediatr Transplant. 2012 Jun;16(4):329-34. doi: 10.1111/j.1399-3046.2012.01657.x. Epub 2012 Feb 21.

Abstract

This study reports initial results of the development of the SIAM, a non-adherence risk assessment system for tacrolimus and sirolimus for the pediatric kidney transplant population. Forty-eight youths between 10 and 25 yr of age diagnosed with chronic kidney disease or a kidney transplant used an electronic pill bottle (EM; time stamps each bottle opening) to dispense their medication for at least 30 days or until their next clinic appointment. Youth also completed a self-report adherence measure, and standard deviations were calculated for the last four medication serum trough levels obtained for each patient. Estimation models were developed for each medication (i.e., SIAM(TACRO) and SIAM(SIRO) ) to assign weights to these clinically available adherence measures (self-report and trough levels) for the calculation of a non-adherence risk composite score. SIAM(TACRO) models included both self-report and tacrolimus trough levels and significantly predicted EM. For sirolimus, the model predictive of adherence as measured by EM consisted of the standard deviation of sirolimus trough levels only (SIAM(SIRO) ). Non-adherence risk can be effectively assessed using clinically available assessment tools. However, the best methods for using self-report and trough levels to predict non-adherence likely differ based on the medication for which adherence is being assessed.

摘要

本研究报告了SIAM(一种针对小儿肾移植人群的他克莫司和西罗莫司非依从性风险评估系统)开发的初步结果。48名年龄在10至25岁之间、被诊断患有慢性肾病或接受了肾移植的青少年使用电子药瓶(EM;记录每次药瓶打开的时间戳)分发药物至少30天,或直至他们的下次门诊预约。青少年还完成了一份自我报告依从性测量,并且计算了每位患者最近四次药物血清谷浓度的标准差。针对每种药物(即SIAM(TACRO)和SIAM(SIRO))开发了估计模型,以便为这些临床可用的依从性测量(自我报告和谷浓度)赋予权重,用于计算非依从性风险综合评分。SIAM(TACRO)模型包括自我报告和他克莫司谷浓度,并且显著预测了EM。对于西罗莫司,通过EM测量的预测依从性的模型仅由西罗莫司谷浓度的标准差组成(SIAM(SIRO))。使用临床可用的评估工具可以有效评估非依从性风险。然而,使用自我报告和谷浓度来预测非依从性的最佳方法可能因所评估依从性的药物而异。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验